Kazakhstan triples pharmaceutical investment as sector expansion strengthens healthcare security

Kazakhstan has recorded a sharp rise in investment in its pharmaceutical industry, with funding directed into medicine and medical device production more than tripling over the past three years, as reported by Kazinform, a partner of TV BRICS.

According to the Ministry of Health, investment in pharmaceutical production reached US$142.8 million in 2025, marking a substantial increase from US$46.9 million in 2023 and US$91.3 million in 2024. The figures demonstrate sustained investor confidence and continued growth in one of the country’s strategically important industries.

Health officials stated that the inflow of capital is being channelled towards the modernisation of production facilities, expansion of manufacturing capacity and localisation of medicines and medical technologies. These efforts form part of a broader strategy aimed at improving national healthcare security and ensuring stable access to essential pharmaceutical products.

The rapid growth in investment reflects the increasing attractiveness of Kazakhstan’s pharmaceutical sector as the country works to develop a more competitive healthcare industry and strengthen its position within regional pharmaceutical supply chains.

Alongside rising investment, Kazakhstan continues to increase the presence of domestically produced medicines and medical devices in the national market. The value share of local pharmaceutical products reached 15 per cent in 2025, up from 14.4 per cent in 2023 and 15.1 per cent in 2024.

Officials note that the introduction of a nationwide medicine labelling and traceability system has provided a more accurate picture of the market and highlighted the growing role of domestic manufacturers. According to the latest data, local producers now account for nearly 40 per cent of pharmaceutical products sold by volume, underscoring the sector’s expanding production capacity.

Authorities confirmed that support measures for the pharmaceutical industry will continue under the national healthcare development framework through 2029. Future priorities include improving access to medicines, increasing domestic production capacity and encouraging the adoption of modern technologies across the healthcare system.